[Chronic tuberculous meningitis in a case of known Mycobacterium kansasii infection].
D000328:Adult; D002056:Burns / Q000150:complications; D002452:Cell Count; D002555:Cerebrospinal Fluid / Q000166:cytology; D002556:Cerebrospinal Fluid Proteins; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D008214:Lymphocytes; D008297:Male; D009161:Mycobacterium / Q000472:pathogenicity*; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D014390:Tuberculosis, Meningeal / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D014397:Tuberculosis, Pulmonary / Q000150:complications*; D014605:Uveitis / Q000188:drug therapy
D002556:Cerebrospinal Fluid Proteins; D011718:Pyrazinamide; D007612:Kanamycin; D004977:Ethambutol; D011239:Prednisolone; D012293:Rifampin
Chronische Meningitis tuberculosa bei bekannter Infektion mit Mycobacterium kansasii